CUMULATIVE SUPPLEMENT 03
March 2006



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2006

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

Cumulative Supplement 03

March 2006

CONTENTS

Note:
Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

CUMULATIVE SUPPLEMENT 03
March 2006

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AVENTIS PHARMACEUTICALS INC (AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
AVENTIS PHARMACEUTICAL PRODUCTS INC (AVENTIS PHARMS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)

DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
CLAY PARK LABS INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
LOREX PHARMACEUTICALS (LOREX)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
MARTEC SCIENTIFIC INC (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
PRIVATE FORMULATIONS INC (PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC (PHARM FORM)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
SANOFI AVENTIS US INC (SANOFI AVENTIS US)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI-AVENTIS US INC (SANOFI AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI INC (SANOFI)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC (SANOFI SYN RES)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
UCB PHARMA INC (UCB PHARMA)	UCB INC (UCB INC)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2005	MAR 2006	SEP 2006	DEC 2006
DRUG PRODUCTS LISTED	11368	11487		
SINGLE SOURCE	2428	2461		
	(21.4%)	(21.4%)		
MULTISOURCE	8851	8937		
	(77.9%)	(77.8%)		
THERAPEUTICALLY EQUIVALENT	8642 (76.04%)	8730 (76.0%)		
NOT THERAPEUTICALLY EQUIVALENT	209 (1.8%)	207 (1.8%)		
EXCEPTIONS[1]	89 (0.8%)	89 (0.8%)		
NEW MOLECULAR ENTITIES APPROVED	11	6		
NUMBER OF APPLICANTS	628	629		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

AB	+	MIKART	650MG;50MG	N89988	001	Oct 26, 1992	Jan	CRLD

SEDAPAP

	@	MAYRAND	650MG;50MG	N88944	001	Oct 17, 1985	Jan	DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	CLONMEL	120MG/5ML;12MG/5ML	N40098	001	Sep 20, 1996	Jan	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	ENDO PHARMS	500MG;7.5MG	N40280	001	Sep 30, 1998	Feb	DISC
	@		650MG;7.5MG	N40280	002	Sep 30, 1998	Feb	DISC
	@		650MG;10MG	N40280	003	Sep 30, 1998	Feb	DISC
	@		750MG;7.5MG	N40281	002	Sep 30, 1998	Feb	DISC
		MIKART	300MG;5MG	N40658	001	Jan 19, 2006	Jan	NEWA
>A>	+		300MG;7.5MG	N40556	002	Mar 24, 2006	Mar	NEWA
AA		VINTAGE PHARMS	325MG;5MG	N40655	001	Jan 19, 2006	Jan	NEWA
AA			325MG;7.5MG	N40656	001	Jan 19, 2006	Jan	NEWA
>D>		HY-PHEN						
>D>	AA	ASCHER	500MG;5MG	N87677	001	May 03, 1982	Mar	DISC
>A>		@	500MG;5MG	N87677	001	May 03, 1982	Mar	DISC

ACETAZOLAMIDE

TABLET; ORAL

ACETAZOLAMIDE

>D>	AB	TARO	250MG	N40195	002	May 28, 1997	Mar	CRLD
>A>	AB	+	250MG	N40195	002	May 28, 1997	Mar	CRLD
>D>		DIAMOX						
>D>	AB	DURAMED PHARMS BARR	125MG	N08943	001		Mar	DISC
>A>		@	125MG	N08943	001		Mar	DISC
>D>	AB	+	250MG	N08943	002		Mar	DISC
>A>		@	250MG	N08943	002		Mar	DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

	AT	VINTAGE	2%;1%	N40609	001	Feb 06, 2006	Jan	NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

	@	GENPHARM	0.09MG/INH	N73045	001	Aug 19, 1997	Feb	DISC
	@	PLIVA	0.09MG/INH	N74072	001	Aug 01, 1996	Feb	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

>A>	AN	RXELITE	EQ 0.083% BASE	N77569	001	Apr 04, 2006	Mar	NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

	+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML	N21163	001	May 18, 2000	Jan	CAHN

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

	+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30UGM/ML	N21559	001	Jun 16, 2003	Jan	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB		MYLAN	0.5MG	N77391	002	Jan 26, 2006	Jan	NEWA
AB			1MG	N77391	003	Jan 26, 2006	Jan	NEWA
AB			2MG	N77391	004	Jan 26, 2006	Jan	NEWA
AB			3MG	N77391	001	Jan 26, 2006	Jan	NEWA

XANAX XR

AB		PHARMACIA AND UPJOHN	0.5MG	N21434	001	Jan 17, 2003	Jan	CFTG
AB			1MG	N21434	002	Jan 17, 2003	Jan	CFTG
AB			2MG	N21434	003	Jan 17, 2003	Jan	CFTG
AB	+		3MG	N21434	004	Jan 17, 2003	Jan	CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB		AMIDE PHARM	100MG	N77659	001	Feb 23, 2006	Feb	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB		PADDOCK	EQ 12% BASE	N76829	001	Feb 07, 2006	Jan	NEWA

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	N62058	001		Jan	CAHN
AB			500MG	N62058	002		Jan	CAHN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	125MG/5ML	N62059	001		Jan	CAHN
AB			250MG/5ML	N62059	002		Jan	CAHN

TABLET; ORAL

AMOXICILLIN

>A> AB		HIKMA	875MG	N65255	001	Mar 29, 2006	Mar	NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

	@	AM ANTIBIOTICS	EQ 250MG BASE	N61602	001		Jan	CAHN
	@		EQ 500MG BASE	N61602	002		Jan	CAHN

FOR SUSPENSION; ORAL

AMPICILLIN TRIHYDRATE

@	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601	001		Jan	CAHN
@		EQ 250MG BASE/5ML	N61601	002		Jan	CAHN

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)

ERAXIS

+	VICURON	50MG/VIAL	N21632	001	Feb 17, 2006	Feb	NEWA

ANISINDIONE

TABLET; ORAL

MIRADON

@	SCHERING	50MG	N10909	003		Jan	DISC

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

SEPTOCAINE

>A>		DEPROCO	4%;EQ 0.005MG BASE/ML	N22010	001	Mar 30, 2006	Mar	NEWA
>D>	+		4%;EQ 0.01MG BASE/ML	N20971	001	Apr 03, 2000	Mar	CPOT
>A>	+		4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971	001	Apr 03, 2000	Mar	CPOT

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265	001	Feb 21, 2001	Jan	CAHN

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351	001	Mar 05, 1999	Feb	DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN-DEMI

@	ENDO PHARMS	325MG;2.25MG;0.19MG	N07337	005		Feb	DISC

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

@	PFIZER	125MG/5ML	N50556	001	Mar 23, 1982	Feb	DISC

TABLET; ORAL

SPECTROBID

@	PFIZER	400MG	N50520	001		Feb	DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL
BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	5MG	N77128	001	Mar 08, 2006	Feb	NEWA
AB		10MG	N77128	002	Mar 08, 2006	Feb	NEWA
AB		20MG	N77128	003	Mar 08, 2006	Feb	NEWA
AB		40MG	N77128	004	Mar 08, 2006	Feb	NEWA
AB	BIOKEY	5MG	N76820	001	Feb 03, 2006	Jan	NEWA
AB		10MG	N76820	002	Feb 03, 2006	Jan	NEWA
AB		20MG	N76820	003	Feb 03, 2006	Jan	NEWA
AB		40MG	N76820	004	Feb 03, 2006	Jan	NEWA

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
EMETE-CON

>D>	+ PFIZER	EQ 50MG BASE/VIAL	N16820	001		Mar	DISC
>A>	@	EQ 50MG BASE/VIAL	N16820	001		Mar	DISC

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE

+	JAZZ	1GM/SCOOPFUL	N20576	001	Oct 25, 1996	Feb	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL
TACLONEX

+	LEO PHARM PRODS	0.064%;0.005%	N21852	001	Jan 09, 2006	Jan	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE

AT	AKORN	0.2%	N76439	001	Mar 14, 2006	Feb	NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT

+	ALCON	1%	N20816	001	Apr 01, 1998	Feb	CAHN

BUDESONIDE

SPRAY, METERED; NASAL
RHINOCORT

>D>	ASTRAZENECA	0.032MG/INH	N20746	001	Oct 01, 1999	Mar	CRLD
>A>	+	0.032MG/INH	N20746	001	Oct 01, 1999	Mar	CRLD
>D>	+	0.064MG/INH	N20746	002	Oct 01, 1999	Mar	DISC
>A>	@	0.064MG/INH	N20746	002	Oct 01, 1999	Mar	DISC

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE

AP	+ BEDFORD	0.25MG/ML	N74441	001	Jan 27, 1995	Feb	CRLD

BUMEX

@ ROCHE	0.25MG/ML	N18226	001	Feb 28, 1983	Feb	DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HYDROCHLORIDE

AB	APOTEX INC	75MG	N76143	001	Jan 17, 2006	Jan	NEWA
AB		100MG	N76143	002	Jan 17, 2006	Jan	NEWA

BUSULFAN

INJECTABLE; INJECTION
BUSULFEX

+	PDL BIOPHARMA INC	6MG/ML	N20954	001	Feb 04, 1999	Jan	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
CAFERGOT

@	NOVARTIS	100MG;2MG	N09000	002		Feb	DISC

MIGERGOT

+	G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CRLD

CALCIPOTRIENE

CREAM; TOPICAL
DOVONEX

+	LEO PHARM	0.005%	N20554	001	Jul 22, 1996	Feb	CAHN

OINTMENT; TOPICAL
DOVONEX

+	LEO PHARM	0.005%	N20273	001	Dec 29, 1993	Feb	CAHN

SOLUTION; TOPICAL
DOVONEX

+	LEO PHARM	0.005%	N20611	001	Mar 03, 1997	Feb	CAHN

CALCITONIN, SALMON

INJECTABLE; INJECTION
MIACALCIN

+	NOVARTIS	200 IU/ML	N17808	002	Mar 29, 1991	Jan	CTEC

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

>A>	AB	ROXANE	0.25UGM	N76917	001	Mar 27, 2006	Mar	NEWA

INJECTABLE; INJECTION
CALCITRIOL

AP	GENIX THERAP	0.001MG/ML	N77102	001	Feb 08, 2006	Jan	NEWA

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

@	CLONMEL HLTHCARE	12.5MG	N74423	001	Feb 13, 1996	Jan	DISC
@		25MG	N74423	002	Feb 13, 1996	Jan	DISC
@		50MG	N74423	003	Feb 13, 1996	Jan	DISC
@		100MG	N74423	004	Feb 13, 1996	Jan	DISC
@	ENDO LABS	12.5MG	N74418	001	Feb 13, 1996	Feb	DISC
@		25MG	N74418	002	Feb 13, 1996	Feb	DISC
@		50MG	N74418	003	Feb 13, 1996	Feb	DISC
@		100MG	N74418	004	Feb 13, 1996	Feb	DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

		@ ENDO LABS	25MG;15MG	N74788	001	Dec 29, 1997	Feb	DISC
		@	25MG;25MG	N74788	002	Dec 29, 1997	Feb	DISC
		@	50MG;15MG	N74788	004	Dec 29, 1997	Feb	DISC
		@	50MG;25MG	N74788	003	Dec 29, 1997	Feb	DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

	AP	WATSON LABS	50MG/VIAL	N77383	001	Jan 27, 2006	Jan	NEWA
	AP		150MG/VIAL	N77383	002	Jan 27, 2006	Jan	NEWA
	AP		450MG/VIAL	N77383	003	Jan 27, 2006	Jan	NEWA

INJECTABLE; IV (INFUSION)

CARBOPLATIN

		@ AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247	001	Oct 21, 2004	Feb	DISC
	AP		EQ 50MG/5ML (10MG/ML)	N77266	001	Feb 15, 2006	Jan	NEWA
		@	EQ 150MG/15ML (10MG/ML)	N77247	002	Oct 21, 2004	Feb	DISC
	AP		EQ 150MG/15ML (10MG/ML)	N77266	002	Feb 15, 2006	Jan	NEWA
	AP		EQ 450MG/45ML (10MG/ML)	N77266	003	Feb 15, 2006	Jan	NEWA
	AP		EQ 600MG/60ML (10MG/ML)	N77266	004	Feb 15, 2006	Jan	NEWA
	AP	BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244	004	Jan 20, 2006	Jan	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

>D>	AB	IVAX PHARMS	EQ 500MG BASE	N62766	001	Mar 03, 1987	Mar	CRLD
>A>	AB	+	EQ 500MG BASE	N62766	001	Mar 03, 1987	Mar	CRLD
	AB	TEVA PHARMS	EQ 500MG BASE	N65282	001	Jan 20, 2006	Jan	NEWA
	AB	WESTWARD	EQ 500MG BASE	N65311	001	Feb 07, 2006	Jan	NEWA

DURICEF

		@ WARNER CHILCOTT	EQ 500MG BASE	N50512	001		Jan	DISC

FOR SUSPENSION; ORAL

CEFADROXIL

		RANBAXY	EQ 125MG BASE/5ML	N65115	001	Mar 26, 2003	Feb	CTEC
	AB	TEVA PHARMS	EQ 250MG BASE/5ML	N65278	001	Jan 20, 2006	Jan	NEWA
	AB		EQ 500MG BASE/5ML	N65278	002	Jan 20, 2006	Jan	NEWA

DURICEF

		@ WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527	002		Feb	DISC

TABLET; ORAL

CEFADROXIL

>A>	AB	HIKMA	EQ 1GM BASE	N65260	001	Mar 30, 2006	Mar	NEWA
	AB	+ IVAX PHARMS	EQ 1GM BASE	N62774	001	Apr 08, 1987	Feb	CRLD

DURICEF

		@ WARNER CHILCOTT	EQ 1GM BASE	N50528	001		Jan	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

	AP	ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313	001	Jan 23, 2006	Jan	NEWA
	AP		EQ 2GM BASE/VIAL	N65313	002	Jan 23, 2006	Jan	NEWA
	AP		EQ 10GM BASE/VIAL	N65312	001	Feb 13, 2006	Jan	NEWA

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

	AP	B BRAUN	EQ 1GM BASE/VIAL	N65214	001	Mar 10, 2006	Feb	NEWA

INJECTABLE; INJECTION
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	B BRAUN	EQ 2GM BASE/VIAL	N65214	002	Mar 10, 2006	Feb	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP	AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245	001	Feb 15, 2006	Jan	NEWA
AP		EQ 500MG BASE/VIAL	N65245	002	Feb 15, 2006	Jan	NEWA
AP		EQ 1GM BASE/VIAL	N65245	003	Feb 15, 2006	Jan	NEWA
AP		EQ 2GM BASE/VIAL	N65245	004	Feb 15, 2006	Jan	NEWA

INJECTABLE; INJECTION
CEFTRIAXONE

AP	AM PHARM	EQ 10GM BASE/VIAL	N65252	001	Feb 15, 2006	Jan	NEWA

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

>A>	AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308	001	Mar 29, 2006	Mar	NEWA
>A>	AB		EQ 250MG BASE	N65308	002	Mar 29, 2006	Mar	NEWA
>A>	AB		EQ 500MG BASE	N65308	003	Mar 29, 2006	Mar	NEWA

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	HIKMA	EQ 250MG BASE	N65215	001	Jan 24, 2006	Jan	NEWA
AB		EQ 500MG BASE	N65215	002	Jan 24, 2006	Jan	NEWA

CEPHRADINE

CAPSULE; ORAL
ANSPOR

>D>	AB	GLAXOSMITHKLINE	250MG	N61859	001		Mar	DISC
>A>		@	250MG	N61859	001		Mar	DISC
>D>	AB		500MG	N61859	002		Mar	DISC
>A>		@	500MG	N61859	002		Mar	DISC

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

>A>	AB	PERRIGO	0.77%	N77364	001	Mar 03, 2006	Mar	CAHN
>D>	AB	PERRIGO NEW YORK	0.77%	N77364	001	Mar 03, 2006	Mar	CAHN
	AB		0.77%	N77364	001	Mar 03, 2006	Feb	NEWA

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

>A>	AB	MUTUAL PHARM	50MG	N77208	002	Mar 29, 2006	Mar	NEWA
>A>	AB		100MG	N77208	001	Mar 29, 2006	Mar	NEWA

CIMETIDINE

TABLET; ORAL
CIMETIDINE

		@ ENDO PHARMS	200MG	N74281	001	May 17, 1994	Feb	DISC
		@	300MG	N74281	002	May 17, 1994	Feb	DISC
		@	400MG	N74281	003	May 17, 1994	Feb	DISC

TABLET; ORAL
CIMETIDINE
@ ENDO PHARMS 800MG N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HYDROCHLORIDE
@ ENDO PHARMS EQ 300MG BASE/2ML N74005 001 Aug 31, 1994 Feb DISC

SOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE
@ ENDO PHARMS EQ 300MG BASE/5ML N74251 001 Dec 22, 1994 Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE
>A> AB TARO EQ 10MG BASE N77278 001 Mar 22, 2006 Mar NEWA
>A> AB EQ 20MG BASE N77278 002 Mar 22, 2006 Mar NEWA
>A> AB EQ 40MG BASE N77278 003 Mar 22, 2006 Mar NEWA
>A> AB TEVA PHARMS EQ 10MG BASE N77213 001 Mar 31, 2006 Mar NEWA
>A> AB EQ 20MG BASE N77213 002 Mar 31, 2006 Mar NEWA
>A> AB EQ 40MG BASE N77213 003 Mar 31, 2006 Mar NEWA

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE
AT ALTANA EQ 1% BASE N65254 001 Feb 14, 2006 Jan NEWA

CLOBETASOL PROPIONATE

SPRAY; TOPICAL
CLOBEX
+ GALDERMA LABS LP 0.05% N21835 001 Oct 27, 2005 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE
AB APOTEX EQ 75MG BASE N76274 001 Jan 20, 2006 Jan NEWA
PLAVIX
AB + SANOFI SYNTHELABO EQ 75MG BASE N20839 001 Nov 17, 1997 Jan CFTG

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH VC W/ CODEINE
+ ALPHARMA US PHARMS 10MG/5ML;5MG/5ML;6.25MG/5ML N88764 001 Oct 31, 1984 Jan CTEC
PROMETHAZINE VC W/ CODEINE
@ MORTON GROVE 10MG/5ML;5MG/5ML;6.25MG/5ML N88896 001 Jan 04, 1985 Jan DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE WITH CODEINE SYRUP
AA VINTAGE 10MG/5ML;6.25MG/5ML N40650 001 Jan 31, 2006 Jan NEWA

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL
GASTROCROM
+ AZUR PHARMA 100MG/5ML N20479 001 Feb 29, 1996 Feb CAHN

CYANOCOBALAMIN

>D>		GEL, METERED; NASAL							
>D>		NASCOBAL							
>D>	+	QOL MEDCL	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	DISC	
>A>		@	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	DISC	

CYCLOBENZAPRINE HYDROCHLORIDE

		TABLET; ORAL							
		CYCLOBENZAPRINE HYDROCHLORIDE							
	AB	AMIDE PHARM	5MG	N77291	001	Feb 03, 2006	Jan	NEWA	
>A>	AB	MUTUAL PHARM	5MG	N73541	002	Apr 06, 2006	Mar	NEWA	
	AB	MYLAN	5MG	N73144	002	Feb 03, 2006	Jan	NEWA	
	AB	SANDOZ	5MG	N72854	002	Feb 03, 2006	Jan	NEWA	
	AB	WATSON LABS	5MG	N71611	002	Feb 03, 2006	Jan	NEWA	
			7.5MG	N71611	003	Feb 03, 2006	Jan	NEWA	
		FLEXERIL							
	AB	MCNEIL CONS SPECLT	5MG	N17821	001		Jan	CFTG	

DEFEROXAMINE MESYLATE

		INJECTABLE; INJECTION							
		DEFEROXAMINE MESYLATE							
>A>	AP	SICOR PHARMS	500MG/VIAL	N76806	001	Mar 31, 2006	Mar	NEWA	
>A>	AP		2GM/VIAL	N76806	002	Mar 31, 2006	Mar	NEWA	

DEMECLOCYCLINE HYDROCHLORIDE

		TABLET; ORAL							
		DECLOMYCIN							
>A>		@ GLADES PHARMS LLC	75MG	N50261	001		Mar	CAHN	
>A>	AB		150MG	N50261	002		Mar	CAHN	
>A>	AB	+	300MG	N50261	003		Mar	CAHN	
>D>		@ PROTEIN DESIGN LABS	75MG	N50261	001		Mar	CAHN	
		@	75MG	N50261	001		Feb	CAHN	
>D>	AB		150MG	N50261	002		Mar	CAHN	
	AB		150MG	N50261	002		Feb	CAHN	
>D>	AB	+	300MG	N50261	003		Mar	CAHN	
	AB	+	300MG	N50261	003		Feb	CAHN	

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

		TABLET, EXTENDED RELEASE; ORAL							
		CLARINEX-D 12 HOUR							
	+	SCHERING	2.5MG;120MG	N21313	001	Feb 01, 2006	Feb	NEWA	

DESMOPRESSIN ACETATE

		INJECTABLE; INJECTION							
		DESMOPRESSIN ACETATE							
		@ BEDFORD	0.004MG/ML	N74575	001	Feb 18, 2000	Jan	DISC	
		DESMOPRESSIN ACETATE PRESERVATIVE FREE							
		@ BEDFORD	0.004MG/ML	N74574	001	Feb 18, 2000	Jan	DISC	
		TABLET; ORAL							
		DESMOPRESSIN ACETATE							
	AB	APOTEX	0.1MG	N77414	001	Mar 07, 2006	Feb	NEWA	
	AB		0.2MG	N77414	002	Mar 07, 2006	Feb	NEWA	
	AB	TEVA PHARMS	0.1MG	N77122	001	Jan 25, 2006	Jan	NEWA	
	AB		0.2MG	N77122	002	Jan 25, 2006	Jan	NEWA	

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB	+	DURAMED	0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN
AB	+		0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE

>A>	AP	BAXTER HLTHCARE	EQ 10MG PHOSPHATE/ML	N87702	001	Sep 07, 1982	Mar	CAHN
>D>	AP	ELKINS SINN	EQ 10MG PHOSPHATE/ML	N87702	001	Sep 07, 1982	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

		@ ENDO PHARMS	5MG	N40299	001	May 13, 1999	Feb	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA		VINTAGE	15MG/5ML;6.25MG/5ML	N40649	001	Feb 14, 2006	Jan	NEWA

DIAZEPAM

TABLET; ORAL

DIAZEPAM

>A>	AB	VINTAGE PHARMS	2MG	N77749	001	Mar 31, 2006	Mar	NEWA
>A>	AB		5MG	N77749	002	Mar 31, 2006	Mar	NEWA
>A>	AB		10MG	N77749	003	Mar 31, 2006	Mar	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	ALTANA	0.05%	N76263	001	Dec 20, 2002	Jan	CRLD
		FLORONE						
		@ PHARMACIA AND UPJOHN	0.05%	N17741	001		Jan	DISC
		FLORONE E						
		@ PHARMACIA AND UPJOHN	0.05%	N19259	001	Aug 28, 1985	Jan	DISC

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB	+	TARO	0.05%	N75331	001	May 14, 1999	Jan	CRLD
		FLORONE						
		@ PHARMACIA AND UPJOHN	0.05%	N17994	001		Jan	DISC
		PSORCON						
		@ PHARMACIA AND UPJOHN	0.05%	N19260	001	Aug 28, 1985	Jan	DISC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		SANDOZ	0.25MG/ML	N40481	001	Aug 21, 2003	Jan	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTZAC

AB4		APOTEX INC	120MG	N76395	001	Feb 01, 2006	Jan	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
DILTZAC

AB4	APOTEX INC	180MG	N76395	002	Feb 01, 2006	Jan	NEWA
AB4		240MG	N76395	003	Feb 01, 2006	Jan	NEWA
AB4		300MG	N76395	004	Feb 01, 2006	Jan	NEWA
AB4		360MG	N76395	005	Feb 01, 2006	Jan	NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE

@	IVAX PHARMS	EQ 100MG BASE	N70186	001	Nov 18, 1985	Jan	DISC
@		EQ 150MG BASE	N70187	001	Nov 18, 1985	Jan	DISC
@	SANDOZ	EQ 100MG BASE	N70470	001	Dec 10, 1985	Jan	DISC
@		EQ 150MG BASE	N70471	001	Dec 10, 1985	Jan	DISC

>A> DOLASETRON MESYLATE

>A> INJECTABLE; INJECTION
>A> ANZEMET

>A>	+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624	002	Sep 11, 1997	Mar	CAIN
>A>	+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624	001	Sep 11, 1997	Mar	CAIN
>A>	+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624	003	Dec 11, 2001	Mar	CAIN

>A> TABLET; ORAL
>A> ANZEMET

>A>		SANOFI AVENTIS US	EQ 50MG BASE	N20623	001	Sep 11, 1997	Mar	CAIN
>A>	+		EQ 100MG BASE	N20623	002	Sep 11, 1997	Mar	CAIN

>D> DOLASETRON MESYLATE MONOHYDRATE

>D> INJECTABLE; INJECTION
>D> ANZEMET

>D>		SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML	N20624	002	Sep 11, 1997	Mar	CAIN
>D>	+		EQ 100MG BASE/5ML	N20624	001	Sep 11, 1997	Mar	CAIN
>D>	+		EQ 500MG BASE/25ML	N20624	003	Dec 11, 2001	Mar	CAIN

>D> TABLET; ORAL
>D> ANZEMET

>D>		SANOFI AVENTIS US	EQ 50MG BASE	N20623	001	Sep 11, 1997	Mar	CAIN
>D>	+		EQ 100MG BASE	N20623	002	Sep 11, 1997	Mar	CAIN

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

>D>	AB	PAR PHARM	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	DISC
>A>		@	EQ 75MG BASE	N65055	004	Apr 18, 2005	Mar	DISC
>D>			EQ 150MG BASE	N65055	003	Jul 15, 2005	Mar	DISC
>A>		@	EQ 150MG BASE	N65055	003	Jul 15, 2005	Mar	DISC
>D>	AB	RANBAXY	EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC
>A>			EQ 75MG BASE	N65053	003	Sep 10, 2003	Mar	CTEC

TABLET; ORAL
DOXYCYCLINE

>D>		@ PAR PHARM	EQ 75MG BASE	N65070	003	Dec 30, 2002	Mar	CMFD
>A>			EQ 75MG BASE	N65070	003	Dec 30, 2002	Mar	CMFD

DOXYCYCLINE HYCLATE

TABLET; ORAL
DOXYCYCLINE HYCLATE

AB	PAR PHARM	EQ 20MG BASE	N65287	001	Feb 28, 2006	Feb		NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
YAZ

>A>	+ BERLEX LABS	3MG;0.02MG	N21676	001	Mar 16, 2006	Mar		NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE

>D>	DENTSPLY PHARM	0.02MG/ML;2%	N21381	002		Mar		CRLD
>A>	+	0.02MG/ML;2%	N21381	002		Mar		CRLD

ERYTHROMYCIN

SOLUTION; TOPICAL
A/T/S

AT	TARO PHARMS NORTH	2%	N62405	001	Nov 18, 1982	Feb		CAHN

ESTRADIOL

GEL; TOPICAL
ESTROGEL

	@ ASCEND	0.06%	N21166	001	Feb 09, 2004	Jan		CAHN

GEL, METERED; TOPICAL
ESTROGEL

	+ ASCEND	0.06%	N21166	002	Feb 09, 2004	Jan		CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL
ESTRASORB

	+ ESPRIT PHARMA	0.25%	N21371	001	Oct 09, 2003	Feb		CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL
ENJUVIA

>D>	@ DURAMED	0.3MG	N21443	001	Dec 20, 2004	Mar		CMFD
>A>		0.3MG	N21443	001	Dec 20, 2004	Mar		CMFD
>D>	@	0.45MG	N21443	002	Dec 20, 2004	Mar		CMFD
>A>		0.45MG	N21443	002	Dec 20, 2004	Mar		CMFD
>D>	@	0.625MG	N21443	003	May 10, 2004	Mar		CMFD
>A>		0.625MG	N21443	003	May 10, 2004	Mar		CMFD
>D>	@	1.25MG	N21443	004	May 10, 2004	Mar		CMFD
>A>	+	1.25MG	N21443	004	May 10, 2004	Mar		CMFD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BALZIVA-21

>D>	+ BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	Mar		CRLD
>A>		0.035MG;0.4MG	N76198	001	Apr 22, 2004	Mar		CRLD

TABLET; ORAL-28
OVCON-35

>D>	AB WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar		CRLD

TABLET; ORAL-28
OVCON-35

>A>	AB	+	WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
LOESTRIN 24 FE

		+	WARNER CHILCOTT	0.02MG;1MG	N21871	001	Feb 17, 2006	Feb	NEWA

ETODOLAC

CAPSULE; ORAL
ETODOLAC

			@ ENDO PHARMS	200MG	N74842	001	Jul 17, 1997	Feb	DISC
			@	300MG	N74842	002	Jul 17, 1997	Feb	DISC
>D>	AB		TARO	300MG	N75078	002	Apr 30, 1998	Mar	CRLD
>A>	AB	+		300MG	N75078	002	Apr 30, 1998	Mar	CRLD
>D>			LODINE						
>D>	AB	+	WYETH PHARMS INC	300MG	N18922	003	Jan 31, 1991	Mar	DISC
>A>			@	300MG	N18922	003	Jan 31, 1991	Mar	DISC

TABLET; ORAL
ETODOLAC

			@ ENDO PHARMS	400MG	N74841	001	Jun 27, 1997	Feb	DISC

FENOFIBRATE

CAPSULE; ORAL
LIPOFEN

			CIPHER	50MG	N21612	001	Jan 11, 2006	Jan	NEWA
				100MG	N21612	002	Jan 11, 2006	Jan	NEWA
		+		150MG	N21612	003	Jan 11, 2006	Jan	NEWA

TABLET; ORAL
FENOFIBRATE

	AB	+	TEVA	160MG	N76433	002	May 13, 2005	Jan	CRLD
			TRICOR						
			@ ABBOTT	54MG	N21203	001	Sep 04, 2001	Jan	DISC
			@	160MG	N21203	003	Sep 04, 2001	Jan	DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
FENOLDOPAM MESYLATE

	AP		SANDOZ	EQ 10MG BASE/ML	N77155	001	Feb 15, 2005	Jan	CAHN

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM

			@ CLONMEL HLTHCARE	EQ 600MG BASE	N72326	001	Aug 17, 1988	Jan	DISC

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

>D>			ACTIQ						
>D>			CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Mar	CTNA
>D>		+		EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Mar	CTNA
>D>				EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Mar	CTNA
>D>				EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Mar	CTNA
>D>				EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Mar	CTNA
>D>				EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Mar	CTNA

TROCHE/LOZENGE; TRANSMUCOSAL

>A>		ACTIQ (SUGAR-FREE)						
>A>		CEPHALON	EQ 0.2MG BASE	N20747	001	Nov 04, 1998	Mar	CTNA
>A>	+		EQ 0.4MG BASE	N20747	002	Nov 04, 1998	Mar	CTNA
>A>			EQ 0.6MG BASE	N20747	003	Nov 04, 1998	Mar	CTNA
>A>			EQ 0.8MG BASE	N20747	004	Nov 04, 1998	Mar	CTNA
>A>			EQ 1.2MG BASE	N20747	005	Nov 04, 1998	Mar	CTNA
>A>			EQ 1.6MG BASE	N20747	006	Nov 04, 1998	Mar	CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

		FEXOFENADINE HYDROCHLORIDE						
>A>	AB	DR REDDYS LABS LTD	30MG	N76502	001	Apr 11, 2006	Mar	NEWA
>A>	AB		60MG	N76502	002	Apr 11, 2006	Mar	NEWA
>A>	AB		180MG	N76502	003	Apr 11, 2006	Mar	NEWA

FLUCONAZOLE

TABLET; ORAL

		FLUCONAZOLE						
	AB	GLENMARK PHARMA	50MG	N77253	001	Jan 25, 2006	Jan	NEWA
	AB		100MG	N77253	002	Jan 25, 2006	Jan	NEWA
	AB		150MG	N77253	003	Jan 25, 2006	Jan	NEWA
	AB		200MG	N77253	004	Jan 25, 2006	Jan	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

		FLUMAZENIL						
	AP	SANDOZ	1MG/10ML (0.1MG/ML)	N77071	002	May 03, 2005	Jan	CAHN
	AP		0.5MG/5ML (0.1MG/ML)	N77071	001	May 03, 2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

		AEROSPAN HFA						
	+	FOREST LABS	EQ 78UGM BASE/INH	N21247	001	Jan 27, 2006	Jan	NEWA

FLUORESCEIN SODIUM

>A>		INJECTABLE; INTRAVENOUS						
>A>		FLUORESCITE						
>A>	+	ALCON RES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980	001	Mar 28, 2006	Mar	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

		ADRUCIL						
>D>	AP	SICOR PHARMS	50MG/ML	N40023	001	Oct 18, 1991	Mar	CRLD
>A>	AP	+	50MG/ML	N40023	001	Oct 18, 1991	Mar	CRLD
		FLUOROURACIL						
>D>	AP	AM PHARM	50MG/ML	N40291	001	Mar 24, 1999	Mar	CRLD
>D>	AP	AM PHARM PARTNERS	50MG/ML	N40278	001	Sep 30, 1998	Mar	CRLD
>A>	AP	+	50MG/ML	N40278	001	Sep 30, 1998	Mar	CRLD
>D>	AP		50MG/ML	N40279	001	Sep 30, 1998	Mar	CRLD
>A>	AP	+	50MG/ML	N40279	001	Sep 30, 1998	Mar	CRLD
>A>	AP	+	50MG/ML	N40291	001	Mar 24, 1999	Mar	CRLD
>D>	AP		50MG/ML	N40379	001	Nov 15, 2000	Mar	CRLD
>A>	AP	+	50MG/ML	N40379	001	Nov 15, 2000	Mar	CRLD
>D>	AP	BEDFORD	50MG/ML	N89508	001	Jan 26, 1988	Mar	CRLD

INJECTABLE; INJECTION
FLUOROURACIL

>A>	AP	+	BEDFORD	50MG/ML	N89508	001	Jan 26, 1988	Mar	CRLD
>D>	AP		SICOR PHARMS	50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
>A>	AP	+		50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
>D>	AP			50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
>A>	AP	+		50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
>D>	AP		STERIS	50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD
>A>	AP	+		50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL
FLUTICASONE PROPIONATE

	AB		G AND W LABS	0.005%	N77168	001	Mar 03, 2006	Feb	NEWA

SPRAY, METERED; NASAL
FLONASE

	AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19, 1994	Feb	CFTG

FLUTICASONE PROPIONATE

	AB		ROXANE	0.05MG/SPRAY	N76504	001	Feb 22, 2006	Feb	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

	AB		CARACO	25MG	N75900	001	Feb 23, 2006	Feb	NEWA
	AB			50MG	N75900	002	Feb 23, 2006	Feb	NEWA
	AB			100MG	N75900	003	Feb 23, 2006	Feb	NEWA
>A>	AB		LEINER	25MG	N75888	001	Nov 29, 2000	Mar	CAHN
>A>	AB			50MG	N75888	002	Nov 29, 2000	Mar	CAHN
>A>	AB	+		100MG	N75888	003	Nov 29, 2000	Mar	CAHN
>D>	AB		SANDOZ	25MG	N75888	001	Nov 29, 2000	Mar	CAHN
>D>	AB			50MG	N75888	002	Nov 29, 2000	Mar	CAHN
>D>	AB	+		100MG	N75888	003	Nov 29, 2000	Mar	CAHN

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCARNET SODIUM

	AP		HOSPIRA	2.4GM/100ML	N77174	001	May 31, 2005	Feb	CAHN

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

	AB		SANDOZ	100MG	N75428	001	Jan 24, 2006	Jan	NEWA
	AB			300MG	N75428	002	Jan 24, 2006	Jan	NEWA
	AB			400MG	N75428	003	Jan 24, 2006	Jan	NEWA

TABLET; ORAL
GABAPENTIN

	AB		SANDOZ	600MG	N76120	001	Jan 27, 2006	Jan	NEWA
	AB			800MG	N76120	002	Jan 27, 2006	Jan	NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION
OPTIMARK

		+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937	001	Dec 08, 1999	Jan	CPOT
		+		3309MG/10ML (330.9MG/ML)	N20937	002	Dec 08, 1999	Jan	NEWA
		+		4963.5MG/15ML (330.9MG/ML)	N20937	003	Dec 08, 1999	Jan	NEWA

INJECTABLE; INJECTION
OPTIMARK
\+ MALLINCKRODT 6618MG/20ML (330.9MG/ML) N20937 004 Dec 08, 1999 Jan NEWA
\+ 16.545GM/50ML (330.9MG/ML) N20975 001 Dec 08, 1999 Jan CPOT
OPTIMARK IN PLASTIC CONTAINER
\+ MALLINCKRODT 1654.5MG/5ML (330.9MG/ML) N20976 001 Dec 08, 1999 Jan CPOT
\+ 3309MG/10ML (330.9MG/ML) N20976 002 Dec 08, 1999 Jan NEWA
\+ 4963.5MG/15ML (330.9MG/ML) N20976 003 Dec 08, 1999 Jan NEWA
\+ 6618MG/20ML (330.9MG/ML) N20976 004 Dec 08, 1999 Jan NEWA

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE
AB COBALT 1MG N77280 001 Feb 03, 2006 Jan NEWA
AB 2MG N77280 002 Feb 03, 2006 Jan NEWA
AB 4MG N77280 003 Feb 03, 2006 Jan NEWA
AB GENPHARM 1MG N77486 001 Feb 10, 2006 Jan NEWA
AB 2MG N77486 002 Feb 10, 2006 Jan NEWA
AB 4MG N77486 003 Feb 10, 2006 Jan NEWA

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE
@ ENDO PHARMS 5MG N74378 001 Nov 28, 1994 Feb DISC
@ 10MG N74378 002 Nov 28, 1994 Feb DISC
TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE
>A> AB WATSON LABS 2.5MG N76467 003 Mar 27, 2006 Mar NEWA
GLUCOTROL XL
>D> PFIZER 2.5MG N20329 003 Aug 10, 1999 Mar CFTG
>A> AB 2.5MG N20329 003 Aug 10, 1999 Mar CFTG

GLYBURIDE

TABLET; ORAL
DIABETA
BX \+ SANOFI AVENTIS US 5MG N17532 003 May 01, 1984 Feb CRLD

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE
>D> AB AGIS INDS 0.05% N76872 001 Dec 16, 2004 Mar CAHN
>A> AB PERRIGO 0.05% N76872 001 Dec 16, 2004 Mar CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE
AO SANDOZ EQ 50MG BASE/ML N76463 001 Jun 24, 2005 Jan CAHN
AO EQ 100MG BASE/ML N76463 002 Jun 24, 2005 Jan CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL
AP SANDOZ EQ 5MG BASE/ML N76464 001 Sep 29, 2004 Jan CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		APRESOLINE							
	@	NOVARTIS	10MG	N08303	004			Feb	DISC
	@		25MG	N08303	001			Feb	DISC
	@		50MG	N08303	002			Feb	DISC
	@		100MG	N08303	005			Feb	DISC
		HYDRALAZINE HYDROCHLORIDE							
AA	+	PLIVA	10MG	N89097	001	Dec 18, 1985		Feb	CRLD
AA	+		25MG	N88467	001	May 01, 1984		Feb	CRLD
AA	+		50MG	N88468	001	May 01, 1984		Feb	CRLD
AA	+		100MG	N89098	001	Dec 18, 1985		Feb	CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

		LISINOPRIL AND HYDROCHLOROTHIAZIDE							
AB		AUROBINDO	12.5MG;10MG	N77606	001	Mar 14, 2006		Feb	NEWA
AB			12.5MG;20MG	N77606	002	Mar 14, 2006		Feb	NEWA
AB			25MG;20MG	N77606	003	Mar 14, 2006		Feb	NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

		A-HYDROCORT							
>A>	AP	HOSPIRA	EQ 100MG BASE/VIAL	N40666	001	Apr 06, 2006		Mar	NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL

		HYDROXYZINE PAMOATE							
>D>	AB	BARR	EQ 100MG HCL	N88488	001	Jun 15, 1984		Mar	CTEC
>A>			EQ 100MG HCL	N88488	001	Jun 15, 1984		Mar	CTEC
		VISTARIL							
>D>	AB	PFIZER	EQ 100MG HCL	N11459	006			Mar	DISC
>A>		@	EQ 100MG HCL	N11459	006			Mar	DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

		BONIVA							
	+	ROCHE	EQ 3MG BASE/3ML	N21858	001	Jan 06, 2006		Jan	NEWA

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

		APIDRA							
>D>	@	SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N21629	001	Apr 16, 2004		Mar	CMFD
>A>	+		1000 UNITS/10ML (100 UNITS/ML)	N21629	001	Apr 16, 2004		Mar	CMFD
>D>	@		300 UNITS/3ML (100 UNITS/ML)	N21629	002	Dec 20, 2005		Mar	CMFD
>A>	+		300 UNITS/3ML (100 UNITS/ML)	N21629	002	Dec 20, 2005		Mar	CMFD

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

		EXUBERA							
		PFIZER	1MG/INH	N21868	001	Jan 27, 2006		Jan	NEWA
	+		3MG/INH	N21868	002	Jan 27, 2006		Jan	NEWA

ISONIAZID

INJECTABLE; INJECTION
ISONIAZID

AP	SANDOZ	100MG/ML	N40648	001	Jul 05, 2005	Jan	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>A> AB	WEST WARD	30MG	N76813	002	Mar 30, 2006	Mar	NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

AP	SANDOZ	15MG/ML	N76271	001	Oct 06, 2004	Jan	CAHN
AP		30MG/ML	N76271	002	Oct 06, 2004	Jan	CAHN

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
PREVACID NAPRAPAC 250 (COPACKAGED)

	TAP PHARM	15MG,N/A;N/A,250MG	N21507	002	Nov 14, 2003	Feb	CTNA

PREVACID NAPRAPAC 375 (COPACKAGED)

	TAP PHARM	15MG,N/A;N/A,375MG	N21507	003	Nov 14, 2003	Feb	CTNA

PREVACID NAPRAPAC 500 (COPACKAGED)

+	TAP PHARM	15MG,N/A;N/A,500MG	N21507	004	Nov 14, 2003	Feb	CTNA

LEVETIRACETAM

TABLET; ORAL
KEPPRA

>D> +	UCB INC	750MG	N21035	003	Nov 30, 1999	Mar	CRLD
>A>		750MG	N21035	003	Nov 30, 1999	Mar	CRLD
>A> +		1GM	N21035	004	Jan 06, 2006	Mar	NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETAXON

@	ALCON	EQ 0.5% BASE	N21114	001	Feb 23, 2000	Feb	CAHN

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
ANESTACON

AT +	POLYMEDICA	2%	N80429	001		Jan	CDFR

LIDOCAINE; TETRACAINE

PATCH; TOPICAL
SYNERA

+	ENDO PHARMS	70MG;70MG	N21623	001	Jun 23, 2005	Feb	CAHN

LISINOPRIL

TABLET; ORAL
LISINOPRIL

AB	AUROBINDO	2.5MG	N77622	001	Feb 22, 2006	Feb	NEWA
AB		5MG	N77622	002	Feb 22, 2006	Feb	NEWA
AB		10MG	N77622	003	Feb 22, 2006	Feb	NEWA
AB		20MG	N77622	004	Feb 22, 2006	Feb	NEWA

TABLET; ORAL
LISINOPRIL

AB	AUROBINDO	30MG	N77622	005	Feb 22, 2006	Feb	NEWA
AB		40MG	N77622	006	Feb 22, 2006	Feb	NEWA

LORAZEPAM

TABLET; ORAL
LORAZEPAM

>A> AB	MYLAN	0.5MG	N77657	001	Mar 16, 2006	Mar	NEWA
>A> AB		1MG	N77657	002	Mar 16, 2006	Mar	NEWA
>A> AB		2MG	N77657	003	Mar 16, 2006	Mar	NEWA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
ADVICOR

+	KOS LIFE	20MG;750MG	N21249	002	Dec 17, 2001	Feb	CMFD

LUBIPROSTONE

CAPSULE; ORAL
AMITIZA

+	SUCAMPO PHARMS	24UGM	N21908	001	Jan 31, 2006	Jan	NEWA

>A> MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

>A> TABLET, CHEWABLE; ORAL
>A> ZEGERID

>A>	SANTARUS	700MG;20MG;600MG	N21850	001	Mar 24, 2006	Mar	NEWA
>A> +		700MG;40MG;600MG	N21850	002	Mar 24, 2006	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

+	PHARMACIA AND UPJOHN	104MG/0.65ML	N21583	001	Dec 17, 2004	Jan	CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGESTROL ACETATE

AB	APOTEX	40MG/ML	N77404	001	Feb 16, 2006	Jan	NEWA

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

	@ ROXANE	600MG	N84332	001		Jan	DISC
	@ SANDOZ	200MG	N14547	002		Jan	DISC
	@	400MG	N14547	001		Jan	DISC
	@	400MG	N80655	001		Jan	DISC
	@ SCHERER LABS	400MG	N83343	001		Jan	DISC
	@ TABLICAPS	400MG	N83494	001		Jan	DISC
AA +	WATSON LABS	200MG	N83304	001		Jan	CRLD
	@	200MG	N85720	001		Jan	DISC
+		400MG	N83308	001		Jan	CRLD
	@	400MG	N85721	001		Jan	DISC
	MILTOWN						
	@ MEDPOINTE PHARM HLC	200MG	N09698	004		Jan	DISC
	@	400MG	N09698	002		Jan	DISC

TABLET; ORAL
TRANMEP

	@ SOLVAY	400MG	N16249	001		Jan	DISC

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
GLUMETZA

BX	DEPOMED INC	500MG	N21748	001	Jun 03, 2005	Jan	CAHN
BX		1GM	N21748	002	Jun 03, 2005	Jan	CAHN

METFORMIN HYDROCHLORIDE

AB	SUN PHARM INDS (IN)	500MG	N77336	001	Feb 09, 2006	Jan	NEWA
AB		750MG	N77336	002	Feb 09, 2006	Jan	NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

BX	UCB INC	40MG	N21259	004	Feb 19, 2006	Feb	NEWA
		50MG	N21259	005	Feb 19, 2006	Feb	NEWA
+		60MG	N21259	006	Feb 19, 2006	Feb	NEWA

RITALIN LA

BX	+ NOVARTIS	40MG	N21284	003	Jun 05, 2002	Feb	CTEC

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL
VUSION

+	BARRIER	0.25%;81.35%;15%	N21026	001	Feb 16, 2006	Feb	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CRLD
>A>	AP	+	EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN

AB	TRIAX PHARMS	EQ 50MG BASE	N50649	001	May 31, 1990	Feb	CAHN
	@	EQ 75MG BASE	N50649	003	Feb 12, 2001	Feb	CAHN
AB	+	EQ 100MG BASE	N50649	002	May 31, 1990	Feb	CAHN

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE

AB	AUROBINDO PHARMA LTD	45MG	N77376	004	Feb 28, 2006	Feb	NEWA
AB	BARR	45MG	N76307	003	Feb 28, 2006	Feb	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION
>A> MITOXANTRONE

>A>	AP	AM PHARM	EQ 20MG BASE/10ML (2MG/ML)	N77496	001	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77496	002	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (2MG/ML)	N77496	003	Apr 11, 2006	Mar	NEWA
>A>	AP	BEDFORD	EQ 20MG BASE/10ML (2MG/ML)	N76611	001	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76611	002	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (2MG/ML)	N76611	003	Apr 11, 2006	Mar	NEWA

INJECTABLE; INJECTION

MITOXANTRONE

>A>	AP	MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871	001	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 25MG BASE/12.5ML (2MG/ML)	N76871	002	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (2MG/ML)	N76871	003	Apr 11, 2006	Mar	NEWA
>A>	AP	SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356	001	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 25MG BASE/12.5ML (2MG/ML)	N77356	002	Apr 11, 2006	Mar	NEWA
>A>	AP		EQ 30MG BASE/15ML (2MG/ML)	N77356	003	Apr 11, 2006	Mar	NEWA

NOVANTRONE

>D>	+	SERONO INC	EQ 20MG BASE/10 MG (2MG/ML)	N19297	001	Dec 23, 1987	Mar	CFTG
>A>	AP +		EQ 20MG BASE/10ML(2MG/ML)	N19297	001	Dec 23, 1987	Mar	CFTG
>D>	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297	002	Dec 23, 1987	Mar	CFTG
>A>	AP +		EQ 25MG BASE/12.5ML (2MG/ML)	N19297	002	Dec 23, 1987	Mar	CFTG
>D>	+		EQ 30MG BASE/15ML (2MG/ML)	N19297	003	Dec 23, 1987	Mar	CFTG
>A>	AP +		EQ 30MG BASE/15ML (2MG/ML)	N19297	003	Dec 23, 1987	Mar	CFTG

MOMETASONE FUROATE

LOTION; TOPICAL

MOMETASONE FUROATE

>D>	AB	AGIS INDS	0.1%	N77180	001	Apr 06, 2005	Mar	CAHN
>A>	AB	PERRIGO	0.1%	N77180	001	Apr 06, 2005	Mar	CAHN
	AB	TARO	0.1%	N76788	001	Mar 15, 2006	Feb	NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

>A>		HOSPIRA	5MG/ML	N19916	002	Mar 30, 2006	Mar	NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN AND POLYMYXIN B SULFATE

	AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106	001	Jan 31, 2006	Jan	NEWA
	AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108	001	Jan 31, 2006	Jan	NEWA

NEOSPORIN G.U. IRRIGANT

	AT +	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001		Jan	CTEC
	AT +		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707	002		Jan	NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARDENE

	+	PDL BIOPHARMA INC	2.5MG/ML	N19734	001	Jan 30, 1992	Jan	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

AFEDITAB CR

	AB1	WATSON LABS	30MG	N75128	001	Mar 10, 2000	Jan	CAHN
	AB1		60MG	N75659	001	Oct 26, 2001	Jan	CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

	AP	AM PHARM	EQ 0.2MG BASE/ML	N77450	001	Feb 10, 2006	Jan	NEWA
	AP		EQ 1MG BASE/ML	N77450	002	Feb 10, 2006	Jan	NEWA

	INJECTABLE; INJECTION							
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
AP	AM PHARM	EQ 0.05MG BASE/ML	N77457	001	Feb 10, 2006	Jan	NEWA	
AP		EQ 0.1MG BASE/ML	N77457	002	Feb 10, 2006	Jan	NEWA	
AP		EQ 0.5MG BASE/ML	N77457	003	Feb 10, 2006	Jan	NEWA	
	OFLOXACIN							
	TABLET; ORAL							
	OFLOXACIN							
AB	DR REDDYS LABS LTD	200MG	N77098	001	Feb 10, 2006	Jan	NEWA	
AB		300MG	N77098	002	Feb 10, 2006	Jan	NEWA	
AB		400MG	N77098	003	Feb 10, 2006	Jan	NEWA	
	OMEPRAZOLE; SODIUM BICARBONATE							
	CAPSULE; ORAL							
	ZEGERID							
	SANTARUS	20MG;1.1GM	N21849	001	Feb 27, 2006	Feb	NEWA	
+		40MG;1.1GM	N21849	002	Feb 27, 2006	Feb	NEWA	
	FOR SUSPENSION; ORAL							
	ZEGERID							
	SANTARUS	20MG/PACKET;1.68GM/PACKET	N21636	001	Jun 15, 2004	Feb	CAIN	
+		40MG/PACKET;1.68GM/PACKET	N21706	001	Dec 21, 2004	Feb	CAIN	
	PENICILLIN V POTASSIUM							
	FOR SOLUTION; ORAL							
	PENICILLIN V POTASSIUM							
AA	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529	001		Jan	CAHN	
AA		EQ 250MG BASE/5ML	N61529	002		Jan	CAHN	
	TABLET; ORAL							
	PENICILLIN V POTASSIUM							
	@ AM ANTIBIOTICS	EQ 250MG BASE	N61528	001		Jan	CAHN	
	@	EQ 500MG BASE	N61528	002		Jan	CAHN	
	PERGOLIDE MESYLATE							
	TABLET; ORAL							
	PERMAX							
AB	VALEANT	EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Jan	CRLD	
AB +		EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Jan	CRLD	
	PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE							
	SYRUP; ORAL							
	PROMETH VC PLAIN							
+	ALPHARMA US PHARMS	5MG/5ML;6.25MG/5ML	N88761	001	Nov 08, 1984	Jan	CTEC	
	PROMETHAZINE VC PLAIN							
	@ MORTON GROVE	5MG/5ML;6.25MG/5ML	N88897	001	Jan 04, 1985	Jan	DISC	
	PHYTONADIONE							
	INJECTABLE; INJECTION							
	AQUAMEPHYTON							
	@ MERCK	1MG/0.5ML	N12223	002		Feb	DISC	
	@	10MG/ML	N12223	001		Feb	DISC	
	VITAMIN K1							
BP +	HOSPIRA	1MG/0.5ML	N87954	001	Jul 25, 1983	Feb	CRLD	
+		10MG/ML	N87955	001	Jul 25, 1983	Feb	CRLD	

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

>A>	AB		IMPAX LABS	5MG	N77248	001	Mar 31, 2006	Mar	NEWA
>A>	AB			7.5MG	N77248	002	Mar 31, 2006	Mar	NEWA

SALAGEN

>D>		+	MGI PHARMA INC	7.5MG	N20237	002	Apr 18, 2003	Mar	CFTG
>A>	AB	+		7.5MG	N20237	002	Apr 18, 2003	Mar	CFTG

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

	AB		UPSHER SMITH	8MEQ	N19123	001	Apr 17, 1986	Jan	CRLD

POTASSIUM CHLORIDE

	AB	+	COPLEY PHARM	8MEQ	N70618	001	Sep 09, 1987	Jan	CRLD

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

			@ CLONMEL HLTHCARE	EQ 1MG BASE	N72705	001	May 16, 1989	Jan	DISC
			@	EQ 5MG BASE	N72707	001	May 16, 1989	Jan	DISC

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

>D>		+	STERIS	25MG/ML	N83398	001		Mar	DISC
>A>			@	25MG/ML	N83398	001		Mar	DISC
>D>		+		50MG/ML	N83764	001		Mar	DISC
>A>			@	50MG/ML	N83764	001		Mar	DISC

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

>D>	AB		WYETH PHARMS INC	12.5MG	N10926	002		Mar	DISC
>A>			@	12.5MG	N10926	002		Mar	DISC
>D>	AB	+		25MG	N10926	001		Mar	DISC
>A>			@	25MG	N10926	001		Mar	DISC

PROMETHAZINE HYDROCHLORIDE

>D>	AB		G AND W LABS	25MG	N40428	001	Feb 05, 2002	Mar	CRLD
>A>	AB	+		25MG	N40428	001	Feb 05, 2002	Mar	CRLD

PROMETHEGAN

		+	G AND W LABS	50MG	N87165	001	Aug 14, 1987	Jan	CRLD

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

>A>	AB		HOSPIRA	10MG/ML	N77908	001	Mar 17, 2006	Mar	NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

>D>	AA		IVAX PHARMS	65MG	N80269	001		Mar	CAHN
>A>	AA		PAR PHARM	65MG	N80269	001		Mar	CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	SANDOZ	1MG/ML	N76400	001	Feb 26, 2003	Jan	CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
REGONOL

AP	SANDOZ	5MG/ML	N17398	001		Jan	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

AB	TORPHARM	EQ 5MG BASE	N76240	001	Jan 26, 2006	Jan	NEWA
AB		EQ 10MG BASE	N76240	002	Jan 26, 2006	Jan	NEWA
AB		EQ 20MG BASE	N76240	003	Jan 26, 2006	Jan	NEWA
AB		EQ 40MG BASE	N76240	004	Jan 26, 2006	Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

BX	+ MUTUAL PHARM	324MG	N89338	001	Feb 11, 1987	Jan	CTEC
BX	WATSON LABS	324MG	N87810	001	Sep 29, 1982	Jan	CMFD

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

	@ CLONMEL HLTHCARE	200MG	N87011	001		Jan	DISC
	@ LANNETT	200MG	N83743	001		Jan	DISC
	@ MUTUAL PHARM	100MG	N81029	001	Apr 14, 1989	Jan	DISC
	@ PHARM FORM	200MG	N83808	001		Jan	DISC
	@ SANDOZ	200MG	N84631	001		Jan	DISC
	@	200MG	N84914	001		Jan	DISC
AB		200MG	N88072	002		Jan	NEWA
	@	300MG	N89839	001	Sep 29, 1988	Jan	DISC
	@ WATSON LABS	200MG	N83288	001		Jan	DISC
	@	200MG	N85140	002		Jan	DISC

RANITIDINE

INJECTABLE; INJECTION
RANITIDINE

AP	BEDFORD	EQ 25MG BASE/ML	N77458	001	Feb 16, 2006	Feb	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL
RANEXA

	+ CV THERAP	500MG	N21526	002	Jan 27, 2006	Jan	NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

>D>	@ JANSSEN PHARMA	3MG	N21444	004	Dec 23, 2004	Mar	CMFD
>A>		3MG	N21444	004	Dec 23, 2004	Mar	CMFD
>D>	@	4MG	N21444	005	Dec 23, 2004	Mar	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL
>A> JANSSEN PHARMA 4MG N21444 005 Dec 23, 2004 Mar CMFD

>A> SELEGILINE

>A> FILM, EXTENDED RELEASE; TRANSDERMAL
>A> EMSAM
>A> SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Mar CAIN
>A> 9MG/24HR N21336 002 Feb 27, 2006 Mar CAIN
>A> + 12MG/24HR N21336 003 Feb 27, 2006 Mar CAIN

>D> SELEGILINE HYDROCHLORIDE

>D> FILM, EXTENDED RELEASE; TRANSDERMAL
>D> EMSAM
>D> SOMERSET 6MG/24HR N21336 001 Feb 27, 2006 Mar CAIN
6MG/24HR N21336 001 Feb 27, 2006 Feb NEWA
>D> 9MG/24HR N21336 002 Feb 27, 2006 Mar CAIN
9MG/24HR N21336 002 Feb 27, 2006 Feb NEWA
>D> + 12MG/24HR N21336 003 Feb 27, 2006 Mar CAIN
+ 12MG/24HR N21336 003 Feb 27, 2006 Feb NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL
>A> OSMOPREP
>A> + SALIX PHARMS 0.398GM;1.102GM N21892 001 Mar 16, 2006 Mar NEWA

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE
AB PUREPAC PHARM 25MG N40353 003 Mar 15, 2006 Feb NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
ANECTINE
AP + SANDOZ 20MG/ML N08453 002 Jan CAHN
@ 50MG/ML N08453 003 Jan CAHN
@ 500MG/VIAL N08453 001 Jan CAHN
@ 1GM/VIAL N08453 004 Jan CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
IMITREX
+ GLAXOSMITHKLINE EQ 6MG BASE/0.5ML (12MG/ML) N20080 001 Dec 28, 1992 Feb CDFR
IMITREX STATDOSE
+ GLAXOSMITHKLINE EQ 4MG BASE/0.5ML (8MG/ML) N20080 002 Feb 01, 2006 Feb NEWA
+ EQ 6MG BASE/0.5ML (12MG/ML) N20080 003 Dec 23, 1996 Feb NEWA

SUNITINIB MALATE

CAPSULE; ORAL
SUTENT
PFIZER 12.5MG N21938 001 Jan 26, 2006 Jan NEWA
25MG N21938 002 Jan 26, 2006 Jan NEWA
+ 50MG N21938 003 Jan 26, 2006 Jan NEWA

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3

>D>		+	ORTHO MCNEIL PHARM	80MG	N19641	001	May 24, 1988	Mar	CFTG
>A>	AB	+		80MG	N19641	001	May 24, 1988	Mar	CFTG

TERCONAZOLE

>A>	AB		PERRIGO NEW YORK	80MG	N77149	001	Mar 17, 2006	Mar	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

	AB	+	UNIMED PHARMS	1%	N21015	001	Feb 28, 2000	Jan	CTEC

TESTOSTERONE

	AB		WATSON LABS	1%	N76737	001	Jan 27, 2006	Jan	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

		@	INDEVUS PHARMS	200MG/ML	N09165	001		Jan	CAHN
	AO	+		200MG/ML	N09165	003		Jan	CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

	AP		TRACE RADIOCHEMICALS	1mCi/ML	N75569	001	Nov 21, 2001	Feb	CAHN

TINIDAZOLE

TABLET; ORAL

TINDAMAX

			MISSION PHARMA	250MG	N21618	001	May 17, 2004	Jan	CAHN
		+		500MG	N21618	002	May 17, 2004	Jan	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

		@	IVAX PHARMS	50MG	N75963	001	Jul 03, 2002	Jan	DISC

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

		@	SANDOZ	25MG/ML	N11685	003		Jan	CAHN
		@		40MG/ML	N12802	001		Jan	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

		+	SANDOZ	5MG/ML	N16466	001		Jan	CAHN
		+		20MG/ML	N16466	002		Jan	CAHN

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

		@	NOVARTIS	50MG	N05914	002		Jan	DISC

>D>		TROLEANDOMYCIN							
>D>		CAPSULE; ORAL							
>D>		TAO							
>D>	+	PFIZER	EQ 250MG BASE	N50336	002			Mar	DISC
>A>		@	EQ 250MG BASE	N50336	002			Mar	DISC
		UNOPROSTONE ISOPROPYL							
		SOLUTION/DROPS; OPHTHALMIC							
		RESCULA							
	+	R TECH UENO LTD	0.15%	N21214	001	Aug 03, 2000		Feb	CAHN
		VECURONIUM BROMIDE							
		INJECTABLE; INJECTION							
		VECURONIUM BROMIDE							
AP	+	BEDFORD	20MG/VIAL	N75549	002	Jun 13, 2000		Jan	CRLD
		ZIDOVUDINE							
		CAPSULE; ORAL							
		RETROVIR							
>D>	+	GLAXOSMITHKLINE	100MG	N19655	001	Mar 19, 1987		Mar	CFTG
>A> AB	+		100MG	N19655	001	Mar 19, 1987		Mar	CFTG
>A>		ZIDOVUDINE							
>A> AB		AUROBINDO PHARMA LTD	100MG	N78128	001	Mar 27, 2006		Mar	NEWA
		ZIPRASIDONE HYDROCHLORIDE							
>A>		SUSPENSION; ORAL							
>A>		GEODON							
>A>	+	PFIZER INC	EQ 10MG BASE/ML	N21483	001	Mar 29, 2006		Mar	NEWA
		ZONISAMIDE							
		CAPSULE; ORAL							
		ZONISAMIDE							
AB		GLENMARK PHARMS	25MG	N77651	001	Jan 30, 2006		Jan	NEWA
AB			50MG	N77651	002	Jan 30, 2006		Jan	NEWA
AB			100MG	N77651	003	Jan 30, 2006		Jan	NEWA
>A> AB		SUN PHARM INDS (IN)	25MG	N77634	001	Mar 17, 2006		Mar	NEWA
>A> AB			50MG	N77634	002	Mar 17, 2006		Mar	NEWA
>A> AB			100MG	N77634	003	Mar 17, 2006		Mar	NEWA

CROMOLYN SODIUM

SPRAY, METERED; NASAL

	CROMOLYN SODIUM							
	ALPHARMA US PHARMS	5.2MG/SPRAY	N74800	001	Jul 26, 2001	Jan	CPOT
+	BAUSCH AND LOMB	5.2MG/SPRAY	N75702	001	Jul 03, 2001	Jan	CRLD
	NASALCROM							
	@ PHARMACIA UPJOHN	5.2MG/SPRAY	N20463	001	Jan 03, 1997	Jan	DISC

KETOPROFEN

TABLET; ORAL

	ACTRON							
	@ BAYER	12.5MG	N20499	001	Oct 06, 1995	Feb	DISC
	ORUDIS KT							
	@ WYETH CONS	12.5MG	N20429	001	Oct 06, 1995	Feb	DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

>D>	IMODIUM A-D							
>D>	+ MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Mar	CDFR

SUSPENSION; ORAL

>A>	IMODIUM A-D							
>A>	+ MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Mar	CDFR

LORATADINE

TABLET; ORAL

	LORATADINE							
	APOTEX	10MG	N76471	001	Feb 14, 2006	Jan	NEWA

MINOXIDIL

AEROSOL, FOAM; TOPICAL

	MEN'S ROGAINE							
+	PHARMACIA AND UPJOHN	5%	N21812	001	Jan 20, 2006	Jan	NEWA

NAPROXEN SODIUM

CAPSULE; ORAL

	NAPROXEN SODIUM							
+	BANNER PHARMACAPS	EQ 200MG BASE	N21920	001	Feb 17, 2006	Feb	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

	NICORETTE							
>A>	GLAXOSMITHKLINE	EQ 2MG BASE	N18612	004	Sep 25, 2000	Mar	CRLD
>A>		EQ 2MG BASE	N18612	003	Dec 23, 1998	Mar	CRLD
>A>		EQ 4MG BASE	N20066	004	Sep 25, 2000	Mar	CRLD
>A>		EQ 4MG BASE	N20066	003	Dec 23, 1998	Mar	CRLD
	NICORETTE (MINT)							
>D>	+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612	003	Dec 23, 1998	Mar	CRLD
>D>	+	EQ 4MG BASE	N20066	003	Dec 23, 1998	Mar	CRLD
	NICORETTE (ORANGE)							
>D>	+ GLAXOSMITHKLINE	EQ 2MG BASE	N18612	004	Sep 25, 2000	Mar	CRLD
>D>	+	EQ 4MG BASE	N20066	004	Sep 25, 2000	Mar	CRLD

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

PERRIGO R AND D	EQ 2MG BASE	N77007	001	Jan 31, 2006	Jan NEWA
	EQ 4MG BASE	N77007	002	Jan 31, 2006	Jan NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

WOCKHARDT	EQ 75MG BASE	N76760	001	Feb 24, 2006	Feb NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2006

NO MARCH 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2006 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM					
021652 001	5034394	Dec 18, 2011	DS DP	D-40	Aug 02, 2007
	5034394*PED	Jun 18, 2012			
	5047407	Nov 17, 2009	DS DP U-257		
	5047407*PED	May 17, 2010			
	5089500	Jun 26, 2009	U-257		
	5089500*PED	Dec 26, 2009			
	5905082	May 18, 2016	DS DP		
	5905082*PED	Nov 18, 2016			
	6294540	May 14, 2018	DS DP U-257		
	6294540*PED	Nov 14, 2018			
ALBUTEROL SULFATE - PROAIR HFA					
021457 001				I-235	Feb 03, 2009
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D					
021762 001				NC	Apr 07, 2008
ALFUZOSIN HYDROCHLORIDE - UROXATRAL					
021287 001	4661491	May 27, 2007	U-706		
ANIDULAFUNGIN - ERAXIS					
021632 001	**>A>** 5965525	Oct 12, 2016	DS DP U-540	NCE	Feb 17, 2011
	>A> 6384013	Mar 19, 2012	DS		
	>A> 6743777	Mar 19, 2012	DP U-540		
	>A> 6960564	Apr 12, 2021	DP U-540		
APREPITANT - EMEND					
021549 001	5145684	Jan 25, 2011	DP		
APREPITANT - EMEND					
021549 002	5145684	Jan 25, 2011	DP		
ARIPIPRAZOLE - ABILIFY					
021436 001				I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY					
021436 002				I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY					
021436 003				I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY					
021436 004				I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY					
021436 005				I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY					
021436 006				I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY					
021713 001	6977257	Apr 24, 2022	DS DP	I-488	Mar 01, 2008
AZELASTINE HYDROCHLORIDE - ASTELIN					
020114 001				D-102	Feb 17, 2009
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX					
021852 001	4866048	Dec 29, 2007	DS DP U-88	NC	Jan 09, 2009
	4866048	Dec 29, 2007	DS DP U-193		
	5763426	Jun 09, 2015	DS DP		
	6753013	Jan 27, 2020	DP U-193		
	6753013	Jan 27, 2020	DP U-88		
BIVALIRUDIN - ANGIOMAX					
020873 001				I-486	Nov 30, 2008
BORTEZOMIB - VELCADE					
021602 001				ODE	Mar 25, 2012

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BRIMONIDINE TARTRATE - ALPHAGAN P								
021770 001		5424078	Jun 13, 2012		DP			
		5424078*PED	Dec 13, 2012					
		6562873	Jul 10, 2021		DP			
		6562873*PED	Jan 10, 2022					
		6627210	Jul 18, 2021		DP			
		6627210*PED	Jan 18, 2022					
		6641834	Jul 28, 2021		DP			
		6641834*PED	Jan 28, 2022					
		6673337	Jul 26, 2021		DP			
		6673337*PED	Jan 26, 2022					
BROMFENAC SODIUM - XIBROM								
021664 001							I-485	Jan 27, 2009
BUDESONIDE - PULMICORT RESPULES								
020929 001		6899099	Dec 23, 2018			U-645		
		6899099*PED	Jun 23, 2019					
BUDESONIDE - PULMICORT RESPULES								
020929 002		6899099	Dec 23, 2018			U-645		
		6899099*PED	Jun 23, 2019					
BUDESONIDE - RHINOCORT								
020746 001		6986904	Apr 29, 2017		DP	U-699		
BUDESONIDE - RHINOCORT								
020746 002		6986904	Apr 29, 2017		DP	U-699		
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)								
021823 001							M-52	Jan 24, 2009
CEFDITOREN PIVOXIL - SPECTRACEF								
021222 001		4839350	Jan 14, 2009	DS	DP			
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK								
021555 002	**>A>**	5690958	Sep 30, 2016		DP			
CICLOPIROX - LOPROX								
020519 001	**>A>**	7018656	Sep 05, 2018		DP			
	>A>	7026337	Apr 02, 2018			U-714		
CONIVAPTAN HYDROCHLORIDE - VAPRISOL								
021697 001		5723606	Mar 03, 2015	DS	DP	U-698		
DESFLURANE - SUPRANE								
020118 001		5617906	Apr 08, 2014		DP			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR								
021605 001		6979463	Mar 28, 2022		DP			
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR								
021313 001	**>A>**	4659716	Apr 21, 2006		DP	U-707	NCE	Dec 21, 2006
	>A>	4659716*PED	Oct 21, 2006				NC	Mar 03, 2008
	>A>	6100274	Jul 07, 2019		DP		PED	Jun 21, 2007
	>A>	6100274*PED	Jan 07, 2010					
	>A>	6709676	Feb 18, 2021		DP	U-707		
DOCETAXEL - TAXOTERE								
020449 001		5750561	Jul 03, 2012		DP		**>A>** I-490	Mar 22, 2009
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT								
021720 001	**>A>**	4895841	Nov 25, 2010	DS	DP	U-713		
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT								
021720 002	**>A>**	4895841	Nov 25, 2010	DS	DP	U-713		
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ								
021676 001							**>A>** NP	Mar 16, 2009
ESOMEPRAZOLE MAGNESIUM - NEXIUM								
021153 001							I-484	Nov 24, 2007
ESOMEPRAZOLE MAGNESIUM - NEXIUM								
021153 002							I-484	Nov 24, 2007
ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA								
021180 001		5876746	Nov 20, 2015		DP	U-514		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE						
021871 001	**>A>**	5552394	Jul 22, 2014	U-1	NP	Feb 17, 2009
FENOFIBRATE - FENOFIBRATE						
076433 001					PC	May 22, 2006
FENOFIBRATE - FENOFIBRATE						
076433 002					PC	May 22, 2006
FENOFIBRATE - LIPOFEN						
021612 001		5545628	Jan 10, 2015	U-701		
FENOFIBRATE - LIPOFEN						
021612 002		5545628	Jan 10, 2015	U-701		
FENOFIBRATE - LIPOFEN						
021612 003		5545628	Jan 10, 2015	U-701		
FLUNISOLIDE - AEROSPAN HFA						
021247 001					NP	Jan 27, 2009
FLUOCINOLONE ACETONIDE - RETISERT						
021737 001		6217895	Mar 22, 2019	DP U-708		
	>A>	6548078	Mar 22, 2019	DP U-708		
FLUOCINONIDE - VANOS						
021758 001					I-487	Mar 02, 2009
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY						
021235 001	**>A>**	RE39030	May 29, 2017	DP U-397		
	>A>	RE39030	May 29, 2017	DP U-396		
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 001	**>A>**	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	>A>	5674472	Oct 07, 2014	DP		
	>A>	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 002	**>A>**	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	>A>	5674472	Oct 07, 2014	DP		
	>A>	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA						
021433 003	**>A>**	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	>A>	5674472	Oct 07, 2014	DP		
	>A>	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50						
021077 001		4992474	Feb 12, 2008	U-211		
		4992474*PED	Aug 12, 2008	U-211		
		5126375	Feb 12, 2008			
		5126375*PED	Aug 12, 2008			
		5225445	Feb 12, 2008	U-211		
		5225445*PED	Aug 12, 2008	U-211		
		6536427	Mar 01, 2011	DP		
		6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50						
021077 002		4992474	Feb 12, 2008	U-211		
		4992474*PED	Aug 12, 2008	U-211		
		5126375	Feb 12, 2008			
		5126375*PED	Aug 12, 2008			
		5225445	Feb 12, 2008	U-211		
		5225445*PED	Aug 12, 2008	U-211		
		6536427	Mar 01, 2011	DP		
		6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50						
021077 003		4992474	Feb 12, 2008	U-211		
		4992474*PED	Aug 12, 2008	U-211		
		5126375	Feb 12, 2008			
		5126375*PED	Aug 12, 2008			
		5225445	Feb 12, 2008	U-211		
		5225445*PED	Aug 12, 2008	U-211		
		6536427	Mar 01, 2011	DP		
		6536427*PED	Sep 01, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES			EXCLUSIVITY CODE(S)		EXCLUSIVITY EXPIRATION DATE	
FROVATRIPTAN SUCCINATE - FROVA											
021006 001	>A>	5464864	Nov	07, 2015			U-436				
FULVESTRANT - FASLODEX											
021344 001		4659516	Oct	01, 2006							
GLIMEPIRIDE - AMARYL											
020496 001								M-54		Nov	28, 2008
								PED		May	28, 2009
GLIMEPIRIDE - AMARYL											
020496 002								M-54		Nov	28, 2008
								PED		May	28, 2009
GLIMEPIRIDE - AMARYL											
020496 003								M-54		Nov	28, 2008
								PED		May	28, 2009
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL											
021700 001		5002953	Sep	17, 2011	DS	DP	U-690				
		5002953*PED	Mar	17, 2012							
		5741803	Apr	21, 2015	DS	DP	U-690				
		5741803*PED	Oct	21, 2015							
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL											
021700 002		5002953	Sep	17, 2011	DS	DP	U-690				
		5002953*PED	Mar	17, 2012							
		5741803	Apr	21, 2015	DS	DP	U-690				
		5741803*PED	Oct	21, 2015							
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL											
021700 003		5002953	Sep	17, 2011	DS	DP	U-690				
		5002953*PED	Mar	17, 2012							
		5741803	Apr	21, 2015	DS	DP	U-690				
		5741803*PED	Oct	21, 2015							
HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT											
021859 001								NCE		Dec	02, 2010
IBANDRONATE SODIUM - BONIVA											
021455 001		4927814	Jul	09, 2007	DS	DP	U-642				
		6143326	Apr	21, 2017			U-642				
IBANDRONATE SODIUM - BONIVA											
021858 001		4927814	Jul	09, 2007	DS	DP	U-700	NDF		Jan	06, 2009
								NCE		May	16, 2008
INSULIN DETEMIR RECOMBINANT - LEVEMIR											
021536 001								I-489		Oct	19, 2008
INSULIN RECOMBINANT HUMAN - EXUBERA											
021868 001		5740794	Apr	21, 2015		DP			>A> NP	Jan	27, 2009
		5997848	Mar	07, 2014			U-704				
		6051256	Mar	07, 2014		DP					
		6257233	May	14, 2019			U-704				
		6423344	Mar	07, 2014		DP					
		6543448	Sep	21, 2014		DP					
		6546929	May	14, 2019			U-704				
		6582728	Jun	24, 2020		DP					
		6592904	Mar	07, 2014		DP					
		6685967	Sep	11, 2018		DP					
		6737045	Mar	07, 2014			U-704				
		RE37872	Feb	12, 2010		DP					
		RE38385	Feb	12, 2010		DP					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - EXUBERA						
021868 002	5740794	Apr 21, 2015	DP		>A> NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
	RE37872	Feb 12, 2010	DP			
	RE38385	Feb 12, 2010	DP			
IPRATROPIUM BROMIDE - ATROVENT HFA						
021527 001	6983743	May 26, 2020	DP			
LANSOPRAZOLE - PREVACID						
020406 001	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
020406 002	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021281 001	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021281 002	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021428 001	6749864	Feb 13, 2007	DP			
LANSOPRAZOLE - PREVACID						
021428 002	6749864	Feb 13, 2007	DP			
LANTHANUM CARBONATE - FOSRENOL						
021468 003	5968976	Mar 19, 2016	DP	U-613		
LANTHANUM CARBONATE - FOSRENOL						
021468 004	5968976	Mar 19, 2016	DP	U-613		
LENALIDOMIDE - REVLIMID						
021880 001	5635517	Jul 24, 2016	DS		ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
LENALIDOMIDE - REVLIMID						
021880 002	5635517	Jul 24, 2016	DS		ODE	Dec 27, 2012
	6045501	Aug 28, 2018		U-694		
	6315720	Oct 23, 2020		U-694		
	6555554	Jul 24, 2016	DP			
	6561976	Aug 28, 2018		U-694		
	6561977	Oct 23, 2020		U-694		
	6755784	Oct 23, 2020		U-694		
	6908432	Aug 28, 2018		U-694		
LIDOCAINE; TETRACAINE - SYNERA						
021623 001					NC	Jun 23, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA					
021906 001	5541206	Jul 30, 2013	DS DP U-688		
	5541206*PED	Jan 30, 2014			
	5635523	Jun 03, 2014	U-688		
	5635523*PED	Dec 03, 2014			
	5648497	Jul 15, 2014	DS DP		
	5648497*PED	Jan 15, 2015			
	5674882	Oct 07, 2014	U-688		
	5674882*PED	Apr 07, 2015			
	5846987	Dec 29, 2012	U-688		
	5846987*PED	Jun 29, 2013			
	5886036	Dec 29, 2012	DP		
	5886036*PED	Jun 29, 2013			
	6037157	Jun 26, 2016	U-688		
	6037157*PED	Dec 26, 2016			
	6703403	Jun 26, 2016	U-688		
	6703403*PED	Dec 26, 2016			
LOVASTATIN; NIACIN - ADVICOR					
021249 001	**>A>** 7011848	Sep 20, 2013	U-712		
LOVASTATIN; NIACIN - ADVICOR					
021249 002	**>A>** 7011848	Sep 20, 2013	U-712		
LOVASTATIN; NIACIN - ADVICOR					
021249 003	**>A>** 7011848	Sep 20, 2013	U-712		
LUBIPROSTONE - AMITIZA					
021908 001				NCE	Jan 31, 2011
MECASERMIN RINFABATE RECOMBINANT - IPLEX					
021884 001	5200509	Apr 06, 2010	DS		
	5681818	Oct 28, 2014	U-697		
MELOXICAM - MOBIC					
020938 001				ODE	Aug 11, 2012
				PED	Feb 11, 2013
MELOXICAM - MOBIC					
020938 002				ODE	Aug 11, 2012
				PED	Feb 11, 2013
MELOXICAM - MOBIC					
021530 001				I-469	Aug 11, 2008
				ODE	Aug 11, 2012
				PED	Feb 11, 2013
				PED	Feb 11, 2009
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION					
021026 001				NP	Feb 16, 2009
MINOXIDIL - MEN'S ROGAINE					
021812 001	6946120	Apr 20, 2019	DP U-702	NDF	Jan 20, 2009
MODAFINIL - PROVIGIL					
020717 001	**>A>** 4927855	May 22, 2007	U-255	**>A>** I-449	Jan 23, 2007
	>A> 4927855*PED	Nov 22, 2007		**>A>** ODE	Dec 24, 2005
	>A> RE37516	Oct 06, 2014	U-255	**>A>** PED	Jul 23, 2007
	>A> RE37516*PED	Apr 06, 2015		**>A>** PED	Jun 24, 2006
MODAFINIL - PROVIGIL					
020717 002	**>A>** 4927855	May 22, 2007	U-255	**>A>** I-449	Jan 23, 2007
	>A> 4927855*PED	Nov 22, 2007		**>A>** ODE	Dec 24, 2005
	>A> RE37516	Oct 06, 2014	U-255	**>A>** PED	Jul 23, 2007
	>A> RE37516*PED	Apr 06, 2015		**>A>** PED	Jun 24, 2006
MORPHINE SULFATE - KADIAN					
020616 004	5378474	Mar 23, 2010			
MORPHINE SULFATE - KADIAN					
020616 005	5202128	Apr 13, 2010			
	5378474	Mar 23, 2010			
MOXIFLOXACIN HYDROCHLORIDE - AVELOX					
021085 001	4990517	Dec 08, 2011	DS DP U-298		
	6610327	Oct 29, 2019	DP U-298		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
021277 001		4990517	Dec 08, 2011	DS DP	U-298	
		6548079	Jul 25, 2020	DP	U-298	
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX						
021598 001	**>A>**	4990517	Dec 08, 2011	DS DP	U-709	
	>A>	4990517*PED	Jun 08, 2012			
NELARABINE - ARRANON						
021877 001		5747472	Feb 20, 2013		U-696	
		5747472	Feb 20, 2013		U-695	
		5747472	Feb 20, 2013		U-689	
		5821236	Feb 20, 2013		U-695	
NIACIN - NIASPAN						
020381 001	**>A>**	7011848	Sep 20, 2013		U-712	
NIACIN - NIASPAN						
020381 002	**>A>**	7011848	Sep 20, 2013		U-712	
NIACIN - NIASPAN						
020381 003	**>A>**	7011848	Sep 20, 2013		U-712	
NIACIN - NIASPAN						
020381 004	**>A>**	7011848	Sep 20, 2013		U-712	
NIACIN - NIASPAN TITRATION STARTER PACK						
020381 005	**>A>**	7011848	Sep 20, 2013		U-712	
NICOTINE POLACRILEX - NICOTINE POLACRILEX						
077007 001					PC	Aug 21, 2006
NICOTINE POLACRILEX - NICOTINE POLACRILEX						
077007 002					PC	Aug 21, 2006
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 001		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 002		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 003		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 004		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN						
019667 005		5753618	May 19, 2015			
		5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
021008 001		5538739	Jul 23, 2013		ODE	Nov 25, 2005
		5538739*PED	Jan 23, 2014		PED	May 25, 2006
		5639480	Jun 17, 2014			
		5639480*PED	Dec 17, 2014			
		5688530	Nov 18, 2014		U-268	
		5688530*PED	May 18, 2015			
		5922338	Jul 13, 2016			
		5922338*PED	Jan 13, 2017			
		5922682	Jul 13, 2016			
		5922682*PED	Jan 13, 2017			
OCTREOTIDE ACETATE - SANDOSTATIN LAR						
021008 002		5538739	Jul 23, 2013		ODE	Nov 25, 2005
		5538739*PED	Jan 23, 2014		PED	May 25, 2006
		5639480	Jun 17, 2014			
		5639480*PED	Dec 17, 2014			
		5688530	Nov 18, 2014		U-268	
		5688530*PED	May 18, 2015			
		5922338	Jul 13, 2016			
		5922338*PED	Jan 13, 2017			
		5922682	Jul 13, 2016			
		5922682*PED	Jan 13, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OCTREOTIDE ACETATE - SANDOSTATIN LAR								
021008 003		5538739	Jul 23, 2013				ODE	Nov 25, 2005
		5538739*PED	Jan 23, 2014				PED	May 25, 2006
		5639480	Jun 17, 2014					
		5639480*PED	Dec 17, 2014					
		5688530	Nov 18, 2014			U-268		
		5688530*PED	May 18, 2015					
		5922338	Jul 13, 2016					
		5922338*PED	Jan 13, 2017					
		5922682	Jul 13, 2016					
		5922682*PED	Jan 13, 2017					
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID								
021849 001	**>A>**	6489346	Jul 16, 2016	DS	DP	U-588		
	>A>	6645988	Jul 16, 2016	DS	DP			
	>A>	6699885	Jul 16, 2016			U-588		
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID								
021849 002	**>A>**	6489346	Jul 16, 2016	DS	DP	U-588		
	>A>	6645988	Jul 16, 2016	DS	DP			
	>A>	6699885	Jul 16, 2016			U-588		
OXALIPLATIN - ELOXATIN								
021492 001		5420319	Aug 09, 2016	DS				
OXALIPLATIN - ELOXATIN								
021492 002		5420319	Aug 09, 2016	DS				
OXALIPLATIN - ELOXATIN								
021759 001		5420319	Aug 08, 2016	DS				
OXALIPLATIN - ELOXATIN								
021759 002		5420319	Aug 08, 2016	DS				
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 001		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 002		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 003		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 004		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 005		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 006		4843086	Jun 27, 2006			U-231		
QUETIAPINE FUMARATE - SEROQUEL								
020639 006		4879288	Sep 26, 2011	DS	DP	U-550		
QUETIAPINE FUMARATE - SEROQUEL								
020639 007		4879288	Sep 26, 2011	DS	DP	U-550		
RALOXIFENE HYDROCHLORIDE - EVISTA								
020815 001		RE38968	Jul 28, 2012			U-662		
		RE38968	Jul 28, 2012			U-657		
	>A>	RE39049	Jul 28, 2012			U-662		
	>A>	RE39049	Jul 28, 2012			U-657		
	>A>	RE39050	Mar 02, 2014			U-662		
	>A>	RE39050	Mar 02, 2014			U-657		
RANOLAZINE - RANEXA								
021526 002		4567264	May 18, 2006	DS			NCE	Jan 27, 2011
		6303607	May 27, 2019			U-705		
		6369062	May 27, 2019		DP			
		6479496	May 27, 2019			U-705		
		6503911	May 27, 2019		DP			
		6525057	May 27, 2019			U-705		
		6562826	May 27, 2019			U-705		
		6617328	May 27, 2019		DP			
		6620814	May 27, 2019			U-705		
		6852724	May 27, 2019			U-705		
		6864258	May 27, 2019			U-705		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE			PATENT CODES		EXCLUSIVITY CODE(S)		EXCLUSIVITY EXPIRATION DATE	
RISEDRONATE SODIUM - ACTONEL											
020835 001								M-52		Jan	24, 2009
RISEDRONATE SODIUM - ACTONEL											
020835 002								M-52		Jan	24, 2009
RISEDRONATE SODIUM - ACTONEL											
020835 003								M-52		Jan	24, 2009
SALMETEROL XINAFOATE - SEREVENT											
020236 001		4992474	Feb	12,	2008						
		4992474*PED	Aug	12,	2008						
		5126375	Feb	12,	2008						
		5126375*PED	Aug	12,	2008						
		5225445	Feb	12,	2008		U-182				
		5225445*PED	Aug	12,	2008						
SALMETEROL XINAFOATE - SEREVENT											
020692 001		4992474	Feb	12,	2008						
		4992474*PED	Aug	12,	2008						
		5126375	Feb	12,	2008						
		5126375*PED	Aug	12,	2008						
		5225445	Feb	12,	2008		U-211				
		5225445*PED	Aug	12,	2008						
SELEGILINE - EMSAM											
021336 001	**>A>**	RE34579	Aug	18,	2007	DS	DP U-711	NDF		Feb	27, 2009
SELEGILINE - EMSAM											
021336 002	**>A>**	RE34579	Aug	18,	2007	DS	DP U-711	**>A>** NDF		Feb	27, 2009
SELEGILINE - EMSAM											
021336 003	**>A>**	RE34579	Aug	18,	2007	DS	DP U-711	**>A>** NDF		Feb	27, 2009
SEVELAMER HYDROCHLORIDE - RENAGEL											
021179 001	**>A>**	7014846	Aug	11,	2013		DP U-246				
SEVELAMER HYDROCHLORIDE - RENAGEL											
021179 002	**>A>**	7014846	Aug	11,	2013		DP U-246				
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP											
021892 001								**>A>** NP		Mar	16, 2009
SORAFENIB TOSYLATE - NEXAVAR											
021923 001								ODE		Dec	20, 2012
SUNITINIB MALATE - SUTENT											
021938 001		6573293	Feb	15,	2021	DS	DP U-703	NCE		Jan	26, 2011
SUNITINIB MALATE - SUTENT											
021938 002		6573293	Feb	15,	2021	DS	DP U-703	NCE		Jan	26, 2011
SUNITINIB MALATE - SUTENT											
021938 003		6573293	Feb	15,	2021	DS	DP U-703	NCE		Jan	26, 2011
TACROLIMUS - PROGRAF											
050708 001								**>A>** ODE		Mar	29, 2013
TACROLIMUS - PROGRAF											
050708 002								**>A>** ODE		Mar	29, 2013
TACROLIMUS - PROGRAF											
050708 003								**>A>** ODE		Mar	29, 2013
TACROLIMUS - PROGRAF											
050709 001								**>A>** ODE		Mar	29, 2013
TERIPARATIDE RECOMBINANT HUMAN - FORTEO											
021318 001		6977077	Aug	19,	2019		U-597				
THYROTROPIN ALFA - THYROGEN											
020898 001								M-53		Jan	23, 2009
TREPROSTINIL SODIUM - REMODULIN											
021272 001		5153222	Oct	06,	2014		U-455				
TREPROSTINIL SODIUM - REMODULIN											
021272 002		5153222	Oct	06,	2014		U-455				
TREPROSTINIL SODIUM - REMODULIN											
021272 003		5153222	Oct	06,	2014		U-455				

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL SODIUM - REMODULIN					
021272 004	5153222	Oct 06, 2014	U-455		
ZANAMIVIR - RELENZA					
021036 001				**>A>** I-491	Mar 29, 2009
ZOLEDRONIC ACID - ZOMETA					
021223 001	**>A>** 4939130	Sep 02, 2012	DS DP U-53		
ZOLEDRONIC ACID - ZOMETA					
021223 002	**>A>** 4939130	Sep 02, 2012	DS DP U-53		

Footnote:
1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
DS = Drug Substance claim
DP = Drug Product claim
U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm